Updates

3rd July 2026 BSE Ltd National Stock Exchange of India Ltd Phiroze Jeejeebhoy Towers Exchange Plaza, Plot No. C/1, G Block, Dalal Street Bandra-Kurla Complex, Bandra (East), Mumbai – 400 001 Mumbai – 400 051 Scrip Code: 506690 Symbol – UNICHEMLAB Dear Sir/Madam, Sub: BUSINESS RESPONSIBILITY AND SUSTAINABILITY REPORT Please find enclosed Business Responsibility and Sustainability Report for the financial year 2025-26. Kindly take the same on your record. Thanking you, For UNICHEM LABORATORIES LIMITED PRADEEP BHANDARI Head – Legal & Company Secretary Encl.: a/a ANNEXURE G Business Responsibility and Sustainability Report SECTION A: GENERAL DISCLOSURES I. Details of listed entity 1 Corporate Identity Number (CIN) of the Company L99999MH1962PLC012451 2 Name of the listed entity Unichem Laboratories Limited 3 Year of Incorporation 22nd August 1962 4 Registered office address 47, Kandivli Industrial Estate, Kandivli (West), Mumbai – 400 067 5 Corporate office address 47, Kandivli Industrial Estate, Kandivli (West), Mumbai – 400 067 6 E-mail ID shares@unichemlabs.com 7 Telephone 022 66474100 8 Website www.unichemlabs.com 9 Financial year for which reporting is being done 1st April 2025 – 31st March 2026 10 Name of the Stock Exchange(s) where shares are listed BSE Limited and National Stock Exchange of India Limited 11 Paid-up capital ₹ 14.08 crores 12 Name and contact details (telephone, Mr. Pabitrakumar Bhattacharyya email address) of the person who may be Managing Director & Chief Executive Officer contacted in case of any queries on Telephone 022 66474100 the BRSR report shares@unichemlabs.com 13 Reporting boundary Standalone basis 14 Name of assurance provider NA 15 Type of assurance obtained NA II. Products/services 16. Details of business activities (accounting for 90% of turnover) Sr. No. Description of main activity Description of business activity % of turnover a Manufacture and Sale of pharmaceutical products Drugs and Pharmaceuticals 100% 17. Products/services sold by the entity (accounting for 90% of the entity’s turnover) Sr. No. Product/Service NIC Code % of total turnover contributed a Manufacture of Allopathic Medicines Class 2100/Sub class 21002 100% III. Operations 18. Number of locations where plants and/or operations/offices of the entity are situated Location Number of Plants Number of R&D Centers Number of Offices Total National 6 1 1 8 International* 0 0 5 5 * including subsidiary companies 19. Markets served by the entity a. Number of locations Locations Number National * (No. of states) 14 International (No. of countries) 65 * Our significant sales constitutes export of finished formulations. ANNEXURE G b. What is the contribution of exports as a percentage of the total turnover of the entity? Our contribution to exports is 97.6% of our total turnover during FY 2026. c. A brief on types of customers Unichem manufactures and markets a large basket of APIs as well as pharmaceutical formulations as branded and simple generics in several regulated and unregulated markets around the world. The company’s products cater to a diverse range of therapeutic areas such as cardiology, gastroenterology, diabetology, psychiatry, neurology, anti-bacterial, anti-infective and pain management. Unichem products are mainly sold to its wholly owned subsidiaries based out of India. Our ultimate customers are the patients who use our products which are served through Distributors, health care professionals and Government Institutions across the globe. IV. Employees 20. Details as at the end of Financial Year a. Employees and workers (including differently abled) Sr. No. Particulars Total (A) Male Female No. (B) % (B/A) No. (C) % (C/A) EMPLOYEES 1. Permanent (D) 1,878 1,619 86.21 259 13.79 2. Other than Permanent (E) 29 23 79.31 6 20.69 3. Total employees (D + E) 1,907 1,642 86.10 265 13.90 WORKERS 4. Permanent (F) 902 901 99.89 1 0.11 5. Other than Permanent (G) 6 6 100.00 0 0.00 6. Total workers (F + G) 908 907 99.89 1 0.11 b. Differently abled employees and workers Sr. No. Particulars Total (A) Male Female No. (B) % (B/A) No. (C) % (C/A) DIFFERENTLY ABLED EMPLOYEES 1. Permanent (D) 3 2 66.67 1 33.33 2. Other than Permanent (E) 0 0 0 0 0 3. Total differently abled employees (D+E) 3 2 66.67 1 33.33 DIFFERENTLY ABLED WORKERS 4. Permanent (F) 0 0 0 0 0 5. Other than permanent (G) 0 0 0 0 0 6. Total differently abled workers (F+G) 0 0 0 0 0 21. Participation/inclusion/representation of women Particulars Total (A) No. & Percentage of Females No. (B) % (B/A) Board of Directors 6 1 16.67 Key Management Personnel* 2 - - * Key Management Personal (KMP) mentioned here consists of Company Secretary and CFO. Managing Director is considered in Board of Directors and not in KMP. 22. Turnover rate for permanent employees (Disclose trends for the past 3 years) Sr. No. Particulars FY 2026 (%) FY 2025 (%) FY 2024 (%) Turnover rate in current Turnover rate in previous Turnover rate in year financial year financial year previous to the previous financial year Male Female Total Male Female Total Male Female Total a Permanent Employees 32.63 20.90 31.05 34.28 24.95 33.05 32.07 24.30 31.03 b Permanent Workers 31.11 66.67 31.17 23.06 85.71 23.29 20.89 18.18 20.87 57 ANNUAL REPORT 2025-2026 ANNEXURE G V. Holding, subsidiary and associate companies (including joint ventures) 23. (a) Names of holding/subsidiary/associate companies/joint ventures Sr. No. Name (A) Nature of % shares held Does entity at column A, participate Association by listed entity in BRSR initiatives of listed entity? 1 Unichem Pharmaceuticals (USA) Inc Subsidiary 100% The Company encourages its 2 Niche Generics Limited, UK subsidiaries to participate in its 3 Unichem Farmaceutica Do Brasil Lta business responsibility activities 4 Unichem S.A. Proprietary Limited wherever applicable. 5 Unichem (China) Pvt Limited 6 Synchron Research Services Private Limited Associate 32.11% VI. CSR Details 24. (i) Whether CSR is applicable as per section 135 of Companies Act, 2013: In terms of Section 135(1) of the Companies Act, 2013 (“Act”), CSR is applicable to the Company. However, in terms of Section 135(5) of the Act, there was no mandatory requirement for the Company to spend on CSR activities for the FY 2026 due to net average loss for immediately preceding three years. (ii) Turnover (in `.) : 1,412.29 crores (iii) Net worth (in `.) : 2,627.10 crores VII. Transparency and Disclosure Compliances 25. Complaints/grievances on any of the principles (Principles 1 to 9) under the National Guidelines on Responsible Business Conduct Stakeholder Grievance FY 2026 FY 2025 group from Redressal No. of Complaints No. of Complaints whom Mechanisms Filed during Pending Remarks Filed during Pending Remarks complaint in Place the year resolution at the year resolution at is received (If Yes, then close of the year close of the year provide web-link for grievance redressal policy) Customers Yes 285 26 All pending 227 36 All pending complaints are complaints are being investigated being investigated and will be resolved and will be resolved in due course in due course Shareholders and Yes 4 0 NA 13 0 NA investors Employees and Yes 2 0 NA 0 0 NA workers Value Chain Yes 0 0 NA 0 0 NA Partners Communities Yes 0 0 NA 0 0 NA Others Yes 0 1 Detailed in 0 1 Detailed in Principle no. 6, Principle no. 6, point no. 13 point no. 13 • The Quality Assurance (QA) team reviews all customer complaints related to product quality and follows established Standard Operating Procedures (SOPs) for receiving, investigating, and responding to such concerns. Customers may submit complaints through designated email IDs provided by the QA or business teams. For consistency, prior-year data has been regrouped and reclassified to align with current-year reporting. Additionally, region-specific toll-free numbers are available and managed by external Pharmacovigilance service agencies. A dedicated email ID is also provided for reporting urgent safety issues or med [Showing first 8,000 characters — download PDF for full document]